Annexon stock falls on eye disease data; JPMorgan downgrades

Annexon (ANNX) shares lost ~58% on Thursday after it geographic atrophy candidate ANX007 failed in a Phase 2 trial and JPMorgan downgraded the stock. Read more here.

Related Keywords

California ,United States ,New York ,Brisbane ,Queensland ,Australia ,Malcolm Kuno ,Pete Stavropoulos ,Cantor Fitzgerald ,Wall Street New York City ,